A study to assess the long-term safety of SAGE-718 in participants with Huntington’s disease
Phase 3 study testing SAGE-718 to assess its safety and tolerability in people with Huntington's disease.
Recruitment endedPhase IIINot specifiedISRCTNTreatment trial
Recruiting in: United States
Sponsor: Sage Therapeutics (United States)
Preparing a short plain-English summary.